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Abstract -MiR-204 and211 enforcedexpression inmurinemesenchymal stromal cells (MSCs)hasbeen shown to
induce adipogenesis and impair osteogenesis, through RUNX2 down-modulation. This mechanism has been
suggested to play a role in osteoporosis associated with obesity. However, two further fundamental MSC
functions, chondrogenesis and hematopoietic supporting activity, have not yet been explored. To this end, we
transduced, by a lenti-viral vector, miR-204 and 211 in a model primary human MSC line, opportunely chosen
among our MSC collection for displaying all properties of canonical bone marrow MSCs, except adipogenesis.
Enforced expression ofmiR-204&211 in these cells, rescued adipogenesis, and inhibited osteogenesis, as previously
reported in murine MSCs, but, surprisingly, also damaged cartilage formation and hematopoietic supporting
activity, which were never explored before. RUNX2 has been previously indicated as the target of miR-204&211,
whose down modulation is responsible for the switch from osteogenesis to adipogenesis. However, the additional
disruption of chondrogenesis and hematopoietic supporting activity, which we report here, might depend on
diversemiR-204&211 targets.To investigate thishypothesis, permanentRUNX2knock-downwasperformed.Sh-
RUNX2 fully reproduced the phenotypes induced bymiR-204&211, confirming thatRUNX2 downmodulation is
themajor event leading to the reported functionalmodificationonourMSCs. It seemsthusapparent thatRUNX2,
a recognized master gene for osteogenesis, might rule all four MSC commitment and differentiation processes.
Hence, the formerly reported role ofmiR204&211 andRUNX2 in osteoporosis and obesity, coupledwith our novel
observation showing inhibition of cartilage differentiation and hematopoietic support, strikingly resemble the
clinical traits ofmetabolic syndrome,where osteoarthritis, osteoporosis, anaemia and obesity occur together. Our
observations, corroborating and extending previous observations, suggest that miR-204&211–RUNX2 axis in
humanMSCs ispossibly involved in thepathogenesis of this rapidly growingdisease in industrialized countries, for
possible therapeutic intervention to regenerate former homeostasis.
Keywords: Mesenchymal stromal cells, miR-204&, RUNX2, cartilage, hematopoietic support activity,
osteogenesis, adipogenesis1 Introduction
Mesenchymal stromal cells (MSCs) represent the
second stem cell population residing in bone marrow
(BM) [33,37], wherein they provide both the reservoir foraltieri@iss.it
penAccess article distributed under the terms of the CreativeCom
which permits unrestricted use, distribution, and reproduction iskeletal cell turn-over and “the soil” for parenchymal cells
“seeds”, i.e. hematopoietic stem cells (HSCs). MSCs are
endowed with extensive proliferation, equal or longer than
threemonths in vitro, the ability to differentiate in at least
four structural lineages, osteoblasts, chondroblasts, adi-
poblasts and reticular stromal cells supporting HSCs; the
capability to produce huge amounts of multiple growthmonsAttribution License (http://creativecommons.org/licenses/by/4.0),
n any medium, provided the original work is properly cited.
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regulator, nurturing and regenerative potential [30,33,37].
Although MSCs were first discovered in BM, other tissue-
specificMSCshavebeen recently identified and categorized
on the basis of their antigen expression signatures and cell
differentiation spectra. Tissue-specific MSCs partly over-
lap with pericytes and span aubiquitous distribution in
human tissues as structural cells [24,30]. We first isolated
and characterized, through four lineages, MSCs in bone
marrow [33]. Subsequently, we isolated and banked tissue-
specificMSCs from amnion, foetal liver, tonsil, dental pulp,
lung, bowel [24,30] and dermal connective tissue. Colonic
(C-) MSCs were subjected to in depth analysis and
comparison to BM-MSCs, classified, both functionally
and by smooth muscle actin expression, in peri-cryptic and
inter-cryptic myofibroblasts [24,30]. Apical peri-cryptic
myofibroblasts are in close contactwith intestinal epithelial
stem cells, wherein they nurture, regulate and maintain
them in the intestinal niche, similarly to the hematopoietic
niche in the BM. Apical or peri-cryptal myofibroblasts
hierarchically represent the highest intestinal MSC rank,
i.e. the closest to BM-MSCs. Inter-cryptal MSCs, on the
other hand, represent the progeny of the former, mainly
devoted to the structural function of holding the crypts in
place. In the present study we utilized primary peri-cryptic
C-MSCs endowed with all the BM-MSCs functions except
adipogenesis, to assay the effect of enforced expression of
miR-204&211 on their whole differentiation spectrum.
MicroRNAs (miRNAs) are 20–22 nt long single
stranded RNAs that regulate gene expression by
targeting complementary nucleic acid sequences
[7,28,32,1,22,34,13,3]. Micro-RNAs play a regulatory role
in virtually all cellular functions, including stemness [32],
plasticity [1] and differentiation in many stem cell types
including MSCs [32,1,22,34,13,3,11]. A growing clinical
interest is arousing around miRas diagnostic and thera-
peutic tool for several diseases. MiR-204 and 211 enforced
expression in murineMSCs have been previously shown to
induce adipogenesis and repress osteogenesis, by targeting
RUNX2 [14,17]. Being bone formation inter-wined with
chondrogenesis, we seek to explore their effect of on
cartilage formation. In bone development, in fact,
chondro- and osteo-genesis are coordinated developmental
processes, since bones form from cartilage cores by
endochondral ossification [8,18,5] head and neck bones
excluded for carrying out membranous ossification. An
overlooked but pivotal lineage, functionally defined as
hematopoietic supporting activity, is also dependent on
MSCs, as constituents of the so called “hematopoietic
niche”, i.e. the soil for HSCs and their siblings [29]. The
“hematopoietic niche” is a micro-structural entity whose
best candidate components are reticular stromal cells and
osteoblasts, both pertaining to the MSC lineage
[26,31,35,29]. Prototypes of the “hematopoietic niche”
are the blood islands around the developing embryo or the
erythroblast islands in the red BM.
However, the effect of miR-204&211 on both chondro-
genesis and hematopoietic supporting activity has been
thus far neglected. One major target of miR-204&211 isRUNX2, a known master gene for bone development [4].
We report here that miR-204&211, formerly described to
inhibit osteogenesis and promote adipogenesis [14] in
murine MSCs, reproduce this phenothypein human C-
MSCs and additionally inhibit chondrogenesis and
hematopoietic supporting activity.
Noteworthy, further targets of miR- 204&211, besides
RUNX2, might account for the disruption of chondro-
genesis and hematopoietic supporting activity we report.
Regarding chondrogenesis, we explored CRTAP [5] a
reported virtual target according to Target Scan6.2 (www.
targetscan.org) but it was not decreased bymiR-204&211.
We then performed RUNX2 knock-down and fully
reproduced the miR-204&211 over-expression phenotype,
demonstrating that RUNX2 itself controls all four
canonical MSC differentiation lineages, including carti-
lage formation and hematopoietic supporting activity.2 Materials and methods
2.1 Isolation and characterization of MSCs
The isolation procedure from human colon biopsies
was derived from the BM-MSC isolation [33] detailed
below. BM from healthy donors was purchased from
CAMBREX Poietics cell systems (Gaithersburg, MD).
BM samples were treated for 20min at 20 °C with
RosetteSep human MSC enrichment cocktail (StemCell
Technologies, Vancouver, BC, Canada) composed by
CD3, CD14, CD19, CD38, CD66b, Glycophorin A
tetrameric antibody (Ab) complexes crosslinking unwant-
ed cells with red blood cells, diluted, and centrifuged over
Ficoll-Hypaque gradient for 25min at 300 g at 20 °C.
Enriched cells were collected, washed, and treated with
NH4Cl (StemCell) for 10min in ice to remove residual red
blood cells. CD34 cells were removed by MACS column
(Miltenyi, Bergisch Gladbach, Germany). Enriched cells
were then cultured at sub-clonal density (1–10 cells/cm2)
for 3 weeks in a-medium (Invitrogen, Carlsbad, CA), 20%
fetal calf serum (FCS; StemCell) in T75 flasks at 37 °C in
5% CO2/O2 atmosphere. Half medium was replaced two
times a week until MSCs reached confluence, defined as
passage (P) 0. MSCs were detached by trypsin-ethyl-
enediaminetetraacetic acid solution (Invitrogen) treat-
ment, partly freezed and partly replated. Each weekly
replating or P was defined by a progressive number. Colon
surgical specimens, obtained from patients who signed an
informed consent before undergoing surgical resection of a
tumor lesion, were dissected to separate the compromised
from the normal tissue, the normal tissue fragment was
thoroughly washed with PBS supplemented with 5X
antibiotic/antimycotic (A/A) solution (Invitrogen),
maintained o/n in PBS 5X A/A at 4 °C, treated with
30–45ml 1mMEDTA/EGTA PBS 75’ at 20 °C, vigorous-
ly shaked, then processed as described for BM.
Cells are cultured in controlled CO2/O2 environment
provided by Forma Scientific incubators customized by
BioSpherix C-Chambers and ProOx110 controller for
normoxia or hypoxia settings.
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Collection of CB, isolation of CD34+ cells were
performed as described [36,39].
2.3 Hematopoietic support
BM-MSCs and colon (C)-MSCs were plated at the
saturating density for confluence of 3.6 104/cm2 in 96-
well/plates (Falcon, Franklin Lakes, NJ) in alpha-
medium, 20% MCS selected FCS (Lonza); 1 week before
the start of the long-term culture (LTC) assay [36,39] the
medium was changed to alpha-medium with 10% FCS,
10% Horse S (both from Stem Cell Technologies),
supplemented with 106M hydrocortisone (Sigma, St
Louis, MO) [36,39]. Plates were then seeded with 2 103
CD34+ cord blood (CB)cells and cultured up to 5 weeks at
33 °C in 5% CO2/O2 atmosphere [36,39]. Half volume of
each culture (0.03ml) was harvested weekly and replaced
with fresh medium. Cells weekly recovered from the
harvested medium were counted and seeded in hemato-
poietic multilineage semi-solid clonogenetic assay cultures
for 14 days at 37 °C in 5% CO2/O2 atmosphere [36,39] in
order to allow the growth and differentiation of hemato-
poietic colonies. At week 5, upon termination of LTC
cultures, both cells recovered from the medium and the
cells entrapped in the MSC layers were independently
counted and seeded in hematopoietic clonogenetic assays
[36,39]. Hematopoietic colonies were scored as CFU-
GEMM (Colony Forming Unit-Granulocyte Erythroid
Megacaryocyte Monocyte: large mixed red and white
colonies) BFU-E (Burst Forming Unit-Erythroid: pure
erythroid red colonies) and CFU-GM (white granulocyte
and/or monocyte colonies) after 2 further week secondary
culture under an Olympus inverted microscope.
2.4 MSCs proliferation
BM- and C-derived MSCs were cultured in 75 cm2
flasks, re-fed twice a week with 12.5ml of fresh medium,
detached at confluence, usually once a week, by trypsine-
thylenediaminetetraacetic acid solution (Invitrogen) treat-
ment, counted, partly frozen andpartly reseeded for culture
at 37 °C in 5%CO2/O2 atmosphere. Eachweekly re-seeding
or passage (P) was defined by a progressive number.
2.5 In vitro MSC differentiation
Osteogenic. 3.1 103 MSC/cm2 were seeded in six-
well/plates(BD) in MSCGM (Cambrex, Poietics Cell
Systems) for 24 h at 37 °C in 5% CO2/O2 atmosphere.
MSCGM was replaced with Osteogenesis Induction Medi-
um (Cambrex), and MSCs cultured for 3 weeks with re-
feeding every 3–4 days. Osteoblasts were stained with ALP
and Von Kossa, labeling early and late differentiation,
respectively. Alternatively, in the RUNX2 knock-down,
osteogenic differentiation was assessed by Von Kossa’s
stain alone.
Chondrogenic. 2.5  105 MSC were washed twice at
150g for 5min at 20 °C with incomplete chondrogenic
medium (Cambrex), re-suspended in 0.5ml completemedium (Cambrex) in 15ml polypropylene tube and
cultured for 3 weeks at 37 °C in 5% CO2/O2 atmosphere,
re-feeding every 2–3 days with fresh medium. In RUNX2
knock-down experiments, for immunohistochemistry and
immuno-localization studies, cartilage pellets were fixed in
4% formaldehyde in phosphate buffer, processed for
paraffin embedding and sectioned serially. Five-micron-
thick sections were stained with hematoxylin and eosin
(Sigma-Aldrich) or Alcian Blue (Sigma-Aldrich).
Immuno-histology experiments were performed using
primary antibodies anti-human type II collagen (Col II;
ab53047, Abcam), anti-human type X collagen (Col X;
ab49945, Abcam) and anti-human Sox-9 (sc-20095, Santa
CruzBiotechnology). Immuno-localizationwas completed
with the use of standard peroxidase/diaminobenzidine
(DAB) reaction and counterstained with hematoxylin.
Bright-field light microscopy images were obtained with
the use of a Zeiss Axiophot epifluorescence microscope
(Carl Zeiss, Oberkochen, Germany).
Adipogenic. Confluent MSCs were supplemented with
Adipogenesis inductionmedium for 3 days followed by 1–3
days of culture in maintenance medium (both from
Cambrex). After three cycles of induction/maintenance,
cells were cultured for an additional week with mainte-
nance medium at 37 °C in 5%CO2/O2 atmosphere.
Adipocytes maturation was checked in phase contrast
microscopy, then cultures were fixed and intracellular
lipid droplets stained with oil red-O solution (Sigma-
Aldrich), for further microscope analysis.
2.6 Real time qRT-PCR
RNA was isolated from cells using the “Total RNA
Purification micro Kit” (NorgenBioteK Corp, Canada)
according to the manufacturer’s protocol. Real time
quantification was performed according to the TaqMan
technology (Applied Biosystems, Foster City, CA, USA):
miR-204 (hsa-miR-204-5p) #000508; miR-211 hsa-miR-
211-5p #000514; RNU6B (#001093).
2.7 Lenti-miR204/211 plasmids generation
The Lenti-miR204 and Lenti-miR211 plasmids were
generated by cloning a fragment of the pri- miRNA (from
100 to +135 bp relative to the 50-end of mature miR-204
and from 103 to +143 relative to the 50-end of mature
miR-211, respectively) into the pSP65-U1 cassette
plasmid [7]. The expression cassette was then subcloned
into the the EcoRV site of the lentiviral vector
pRRLcPPT.hPGK.EGFP.WPRE [7]. Empty vetor was
utilized as control (PGK). Infective particles were
produced and utilized as previously described [7,20].
2.8 RUNX2 knockdown
RUNX2 knockdown was obtained by Mission Lenti-
viral shRNA clone SHCLNV-NM_004348 targeting
RUNX2 (Sigma-Aldrich, USA). Mission Lentiviral
Non-Targeting shRNA clone SHC002 (Sigma-Aldrich,
USA) was utilized as control. Lentiviral particles were
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Infection of C3 MSCs was performed as previously
described [28].
2.9 Western blot analysis
Western blot analysis was performed according to
standard procedures either on cultured cells or on
chondrogenic spheres. Antibodies listed below were used
in accordance to the manufacturer’s instructions: RUNX2
(27-K: sc-101145) (Santa Cruz Biotechnology Dallas, TX,
USA); b-ACTIN (Oncogene Research, La Jolla, CA,
USA) and GAPDH (2D9) (OriGene, Rockville, MD,
USA). b-ACTIN and GAPDH were used as loading
controls.
2.10 Statistical analysis
Statistical analysis was performed by one-way
ANOVA and subsequently by Bonferroni post-tests.
Differences are considered statistically significant at
p< 0.05.
3 Results
3.1 MicroRNA 204 & 211 inhibit bone and restore
fat differentiation, but inhibit also cartilage and
hematopoietic support in human MSCs
Intrigued by a former article describing the role ofmiR-
204&211 inmurineMSCdifferentiation [14], we decided to
reproduce these data on our primary human MSCs. To
this end, among the best characterizes MSC lines in our
collection [30], we chose the human smooth muscle actin
(SMA+) peri-cryptic colonic C3-MSCs, comparable, for
their differentiation profile, to the murine cells originally
studied in [14]. The differentiation profile of C3-MSCs is
shown in Figure 1. Human wild-type C3 MSCs, and
control PGKC3 MSCs differentiate along the osteogenic
(Fig. 1A,a) and chondrogenic pathways (Fig. 1A,c), but
not toward the adipogenic one in specific differentiation
culture systems (Fig.1A,b). C3 MSCs over-expressing
miR-204 ormiR-211 partially gainedthe ability to produce
adipocytes (Fig. 1A,b) and decreased the attitude to
differentiate in osteocytes (Fig. 1A,a), as expected [14]. As
a novel finding, since chondrogenesis was not explored
before, miR204 and miR211 impaired cartilage develop-
ment (Fig. 1A,c). We formerly showed that wild-type C3-
MSCs could support hematopoiesis in a 5wk long-term
culture (LTC) system as efficiently as BMMSCs [30]. We,
hence, decided to evaluate this function in C3-MSCs over-
expressing miR-204 or miR-211 in LTC to measure their
support for cord blood CD 34+ hematopoietic progenitors
(HPCs), in vitro. In this system, C3MSCs over-expressing
miR-204 or miR-211maintained the overall hematopoietic
cell number (Fig. 1B, a) similarly to parental cells, but
were largely ineffective in supporting hematopoietic
progenitors (Fig. 1B,b), when compared to control mock
(PGK) transduced C3-MSCs, as evaluated in secondary
clonogenic cultures in semisolid medium derived from theprimal culture. Wild-type BM12-MSCs were included as
LTC-system control, representing standard hematopoiet-
ic supportive cells.
The selectivity of progenitor cell decrease, together
with the maintenance of the total cell number, counted by
dye exclusion, ruled out any not-specific, toxic effect
dependent from C3-MSC infected with miR-204 or 211
(Fig. 1B, a vs b).
3.2 MicroRNA 204 & 211 inversely correlate with
RUNX2, impairing cartilage differentiation
HumanC3-MSCs, have little steady state expression of
miR-204&211 (Fig. 2 A), similarly to reference human BM
BM12-MSCs (Fig. 2A) whereas SMA- inter-cryptic
colonic C6-MSCs [30) express higher levels of miR-204/
211 (Fig. 2A), being a more differentiated cell class. C12 is
an additional SMA+ colonic MSC line similar to C3 [30].
This observationmay suggest that the low expression of
miR-204&211 is linked to a less differentiated cell state.
PGK, miR-204 and 211 infected C3 MSCs were induced in
cartilage spheroids for 1 week, then lysed for protein
extraction (Fig. 2B). Western Blot (WB) analysis demon-
strated thatRUNX-2 protein, a key transcription factor for
osteogenesis, was highly expressed in control PGKC3
MSCs (Fig. 2B). In contrast, C3 MSCs over-expressing
miR-204 ormiR-211, effectively down-modulatedRUNX-2
(Fig. 2B), whereas expression levels of CRTAP gene
product, a key gene for chondrogenesis [5], and a potential
target for miR-204&211, according to Target Scan6.2
(www.targetscan.org), were not altered. GAPDH, the
control protein, remained steady (Fig. 2B). Additional
WB analysis, in undifferentiated SMA+ C3 MSCs
demonstrated that RUNX-2 was expressed as well (Fig.
2C, third lane) whereas it was not in SMA-C6 MSCs (fifth
lane) nor in C13 (fourth lane), an additional SMA-colonic
MSC line [30] (Fig. 2C). More importantly, it was sharply
decreased in C3 over-expressing miR-204 or miR-211 (Fig.
2C, second and first lane, respectively). Actin control
protein, used here, was steady (Fig. 2C). During ex
vivochondrogenesis (Fig. 2D, a) RUNX2 protein expres-
sion wasmaintained up to 2 weeks, then down-regulated at
later times. It was again down-regulated upon miR-204 or
miR-211 over-expression (Fig. 2D, b) in an additional
experiment confirming the former results (in Fig. 2C).
3.3 shRUNX2 inhibits bone and restore fat
differentiation, similar to miR 204&211
overexpression
To rule out that further miR-204&211 targets might
account for the disruption of chondrogenesis and hemato-
poietic supporting activity in C3 MSCs over-expressing
miR-204&211, we permanently knocked-down RUNX2 in
C3 MSCs with a lentivirus containing RUNX2 shRNA
infection. Also in these experiment, the adipogenic
potential was restored (Fig. 3a) whereas the osteoblastic
differentiation was impaired (Fig. 3b), reproducing the
phenotype obtained by miR-204 or 211 over-expression in
Fig. 1A, (b) and (a).
Fig. 1. (A)MiR-204 andmiR-211 inhibition of osteogenesis (a), and chondrogenesis (c) coupled with promotion of adipogenesis (b) in
human C3 colonicMSC line (as indicated by black arrows for intracellular lipid droplets formation). PGK represent C3MSCs infected
with empty vector viral particles. Human C6 colonic MSC line (insert, i) is shown as negative control being unable to differentiate in
cartilage [30]. Scale bar=30mm, 4­0mm. (B) Effect of miR-204 and miR-211 enforced expression in human C3 colonic MSCs
hematopoietic supporting activity. Cord blood CD34+ cells were plated onto C3-MSC layers.Weekly cultures were halved to be refed,
harvested cells were counted (shown in a) and replated in semisolid hematopoietic secondary cultures to evaluate their progenitor cell
content (b). Graphs derive fromone of three different experiments performed in triplicates. C3 represent C3MSCs infected with empty
vector viral particles. BM12-MSCs are included as standard hematopoietic supportive cells. The total number of hematopoietic cells in
LTC was unaffected by miR204&211 (a), whereas the number of hematopoietic progenitors (HPCs) was inhibited (b). At wk 5 the
culturewas terminated harvesting both the cells in suspension (s) and the ones entrapped in the adherent layer (a). Their numbers were
added up to generate wk 5 (s+a) points.
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Fig. 2. (A)Baseline expression ofmiR-204 andmiR-211 in undifferentiatedC3,C6, C12, BM12MSCs byQRealTimePCR.Full scale
bar graph. (B)Modulation of RUNX-2 expression.miR-204 andmiR-211 overexpression inhibit RUNX-2 as evaluated byWestern blot
in C3 MSCs 1wk chondroid cultures. CRTAP, a cartilage master gene and a potential target of miR-204&211 according to Target
Scan6.2 (www.targetscan.org), but not miR and a (www.microrna.org), is not affected in miR 204 and miR 211 overexpressing C3
MSCs, whereas RUNX-2 is significantly decreased. GAPDH is the control protein and is steady. (C) RUNX-2 protein expression level
evaluated in control C3, C3miR204 and C3miR211 compared with wild type C6 and C13 primary human colonic MSCs. Actin is used
as control protein. (D) Modula4tion of RUNX-2 protein expression in wild type C3 MSCs upon induction of chondroid differentiation
(a) or C3 over-expressing miR-204&211 (b). RUNX-2 was down-regulated during ex vivo chondrogenesis (a) Analyses were conducted
on cartilage pellets. MiR-204&211 strongly down-regulated RUNX-2 protein expression in C3 MSCs (b).
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support differentiation as well, similar to miR 204 &
211 over-expression
More interestingly, sRUNX2 shRNA human C3
MSCwere unable to differentiate in cartilage, both at
macroscopic (Fig. 4 A, a) and at microscopic level (Fig.
4A, b), whereas control C3-MSCs fully differentiated to
express Collagen II, X, and Sox 9 (Fig. 4A, c). Finally,
sRUNX2 shRNA human C3 MSC were unable to support
hematopoiesis in LTCs (Fig. 4B). The effect of shRUNX2
on C3 MSCs supporting CB CD34+ cells did not change
themaintenance of the total number of cells up to 5week in
LTC (Fig. 4B, a). However, the progenitor cell fraction,within the total cell number of output in LTC, was deeply
decreased when compared to control C3MSCs or standard
BM6 MSCs supportive activity (Fig. 4B, b). Thus,
RUNX2 knock-down is, by itself, sufficient to replicate
miR-204&211 over-expression phenotype in C3MSC
differentiation.
4 Discussion
Mesenchymal stromal cells (MSCs) represent the
second stem cell population residing in BM [33,37] where
they pair with HSCs. BM-MSCs are endowed with the
ability to differentiate in four canonical lineages, osteo-
blasts, chondroblasts, adipoblasts and reticular stromal
Fig. 3. Effects of RUNX2knock-down in humanC3MSCs differentiation. (a)Oil red-O stained cultures, showingmultiple areas of red
lipid staining in shRUNX2 treated cells (as indicated by black arrowspointing to intracellular lipid droplets formation). (i, ii) Details of
positive oil red-O-staining in treated cells, as seen in transmitted light. No droplets for adipogenic differentiation were observed in
control mock treated-cells. Scale bar=120mm, 40mm, 20mm, 10mm. (b) Strong deposition of mineralized matrix was observed in
mock control cells by Von Kossa’s stain. Weak mineralization detected by Von Kossa method in shRUNX2 transduced cells. Scale
bar=120mm.
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activity. MSCs were first discovered in BM, (other)
tissue-specific MSCs have been recently recognized and
studied [30,27,24,2]. In this manuscript, we utilize primary
peri-cryptic colonic SMA+MSCs endowed with all BM
MSCs functions but adipogenesis [30] to explore the role of
miR-204&211 in their differentiation. Our choice was
based on: (1) human C3-MSCs are endowed with most of
the BM-MSCs functions except adipogenesis [30; (Fig. 1A,
b)]. As apical or peri-cryptal myofibroblasts, they
hierarchically represent the highest intestinal MSC
rank,that is the closest to BM-MSCs. (2) Human C3-
MSCs, have little steady state expression of miR-204&211
(Fig. 1B), similarly to human BM BM12-MSCs (Fig. 1B),
whereas SMA- inter-cryptic colonic C6-MSCs [30] express
higher levels of miR-204/211 (Fig. 1B), being a more
advanced cell.
Human C6MSCs, in fact, are unable to differentiate in
cartilage (Fig. 1A, c, insert i) or to sustain hematopoiesis
(not shown). In addition to C3 SMA+peri-cryptal
myofibroblast line, we explored miR-204&211 expression
in an additional SMA+ line, C12 [30] suggesting the low
expression of miR-204&211 as a candidate stem cell
marker. Inter-cryptal SMA-MSCs, like C6 or C13 [30)
represent the progeny of the SMA+peri-cryptal or apicalmyofibroblasts and are mainly devoted to structurally
hold the intestinal crypts folded. MicroRNAs (miRNAs)
are 20–22 nt not coding single stranded RNAs that fine
tune gene expression by targeting complementary nucleic
acid sequences [7,28,32,1,22,34,13,3]. Micro-RNAs have
been established to play a regulatory role in stemness [32],
plasticity [1] and in differentiation in many stem cell types
including MSCs [32,1,22,34,13,3,11].
MiRNAs are necessary for the development of normal
cartilage, as shown in mice with chondrocytes lacking the
Dicer gene, a key enzyme for micro RNAmaturation, with
severe skeletal defects [15]. Many miRNAs have been
linked to cartilage development [38,9]. However, to date,
no report indicates a role for miR-204&211 in chondro-
genesis, despite the fact that they impair osteogenesis and
by default stimulate adipogenesis, via RUNX2 inhibition
[14]. RUNX2 is a recognized master gene for bone
development [4]. In the developing human skeletal system,
head and neck excluded, chondro- and osteo-genesis are
strictly inter-wined processes. Bone formation starts from
cartilage cores in a path known as endochondral ossifica-
tion [8,18,5,12].
The fourth canonical differentiation pathway for
MSCs, often neglected, is the hematopoietic supporting
activity. Although the “hematopoietic niche” is slowly
Fig. 4. Chondrogenic differentiation capability of C3-MSCs and C3 MSCs RUNX2 knock-down (Aa) Macroscopic views of 5
chondroid spheres made from treated C3 MSCs (shRUNX2), and 5 identically processed control pellets generated from mock treated
C3 MSCs (ctrl). (b) Chondrospheres from mock cells generate satisfactory cartilage. In contrast, treated cells regularly failed to form
good cartilage differentiation. Hematoxylin/Eosin (H/E); Alcian blue/Hematoxylin (Alcian blue/H); Alcian blue stain. Scale
bar=200mm, 100mm. (c) Macroscopic views of 3 chondroid spheres generated from C3MSCs, and 3 pellets generated from C3MSCs
shRUNX2 are shown. Hematoxylin and eosin staining of C3-MSCs (left) pellets induced by culture with chondrogenic medium
(Cambrex) for 3 weeks. Immunostaining of C3-MSCs (left) pellets with anti-human type II collagen (COL II), anti-human type X
collagen (COLX) and anti-human Sox-9 (Sox9) and counterstainedwith hematoxylin. In contrast, RUNX2 knock-down (right) pellets
regularly failed to form good cartilage differentiation (Alcian blue/Hematoxylin). (d)Western Blot analysis of C3MSCs infected with
control lentivirus or shRUNX2 lentivirus. RUNX2 protein is effectively knocked-down. (B) RUNX2 knock-down in human C3 MSCs
supporting hematopoietic cells and progenitors in LTCs. Cord blood CD34+ cells were plated onto C3-MSC layers. Weekly cultures
were halved to be reFed, harvested cells were counted (shown in a) and replated in semisolid hematopoietic secondary cultures to
evaluate their progenitor cell content (b). Graphs derive from one of three different experiments performed in triplicates. C3 MSCs
represent cells infected with missense control viral particles. BM6-MSCs are included as standard hematopoietic supportive cells. The
treatment did not affect the overall survival of hematopoietic cells (a), but selectively decreased the hematopoietic progenitors output
(b). At wk 5 the culture was terminated harvesting both the cells in suspension (s) and the ones entrapped in the adherent layer (a),
which were cumulated to generate the points wk5 (s+a).
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osteoblasts, and reticular stromal cells, all belonging to the
MSCs family have been shown, in vivo, as the only
candidates defining this compartment [29,26,31,35,25].
The closest anatomic counterparts to the concept of
“hematopoietic niche” are the blood islands around the
developing embryo or the erythroblast islands in the red
BM.
Thus, the effect of miR-204&211 on RUNX2, and the
consequent inhibition of osteogenesis, could impact the
whole MSC differentiation spectrum, including cartilage
and hematopoietic support. C3 MSCs are a colonic tri-
lineage precursor primary line derived from SMA+peri-
cryptalmyofibroblasts [30] able to differentiate in osteo-
blasts, chondroblasts and reticular stromal cells support-
ing hematopoiesis, but not toward adipocytes. Their
baseline expression of miR-204&211 is very low, similar to
BM-MSCs, which matches with their stemness functional
similarities. On the other hand, C6 MSCs represent a
colonic uni-lineage precursorprimary line derived from
SMA- inter-cryptal myofibroblasts [30,24,2], with very
restricted differentiation potential. Accordingly, their
baseline expression of miR-204&211 is high. It is thus
conceivable that miR-204&211 expression could regulate
stem cell progression and lineage restriction. C3 MSCs
were chosen as an adequate cell model to confirm (as in [14]
for osteo/adipo switch) and extend (present report for
chondro/hematopoietic support inhibition) the effect of
miR-204&211 over-expression in human MSCs.
Adipogenesis, absent in C3 MSCs, is restored, at least
in part, by miR 204 or 211 gene transfer, which in turn,
impairs not only osteogenesis, but also chondrogenesis and
hematopietic supportive activity in 5wk LTCs. C3-MSCs,
transduced with miR 204 and miR 211, strongly down-
modulate RUNX2 protein, but not CRTAP, a cartilage
specific potential targetfor miR- 204/211 (www.targets
can.org). As a single gene product can be targeted by
multiple miRNA species, and a single microRNA can
target multiple mRNAs [7,28,32,1,22,34,13,3,15,38,9],
additional targets of miR-204&211 might account for
the disruption of chondrogenesis and hematopoietic
supporting activity. Experiments with stable RUNX2
shRNA were performed to rule out the role for other
targets of miR-204&211 impaired chondrogenesis and
hematopoietic supporting activity. These permanent
knock-down experiments fully recapitulated the pheno-
types observed with miR-204&211, thus demonstrating
that RUNX2 itself is necessary for normal chondrogenesis
and to support hematopoiesis in vitro. It would be of great
interest to validate the role of RUNX2 in hematopoietic
supportive activity, as well as for the entire MSC
differentiation spectrum in an in vivo system [26,31,25].
The hematopoietic supporting activity exerted by an
intestinal MSCs subtype is puzzling. It is possible that this
function, originally described in BM-MSCs, could have
adapted in peri-cryptal intestinal myofibroblasts to
nurture intestinal stem cells within the crypts (intestinal
niches), but is versatile enough to support also hemato-
poietic cells. The recent discovery of platelet generationand ectopic hematopoiesis in lung [16] corroborates this
hypothesis. Furthermore, stress hematopoiesis, as known,
can take place in ectopic sites in Cooley’s anemia leading
to facial deformity. MSC supporting activity in tissue
specific niches for highly demanded lineages, like the
hematopoietic and the intestinal epithelia, might allow
permissive cross-lineage colonization, as indicated by their
functional deployment by adenocarcinoma cells [19], or
BM diffusing neuroblastomas. We could thus speculate
that some circulating white hematopoietic precursor
might, when necessary, utilize peri-cryptal myofibro-
blasts, as nurturing pseudo-crypt for a local quick
expansion [21]. This fact highlights the importance of
the MSC-determined microenvironment in maintaining-
normal homeostasis as well as inparticipating in inflam-
matory diseases (Crohn’s disease) and in cancer
progression.
Our data are not in contrast with a former report [10]
showing no major chondrogenic impair by transient
RUNX2 knock-down in a murine cell line. Those data,
obtained with a different technique, might have knocked-
down RUNX2 too shortly to produce the chondrogenic
inhibition. It is thus apparent that RUNX2, a recognized
master gene for osteogenesis, sits at the intersection of
multiple MSC pathways regulating commitment and
differentiation toward all canonical MSC fates. MiR-
204&211 have been already involved in osteoporosis [14]
and obesity [23,6]. Our additional data, i.e., inhibition of
chondrogenesis and hematopoietic supporting activity,
coupled with promotion of adipogenesis and depression of
osteogenesis, strikingly recall the clinical traits of
metabolic syndrome, where obesity, osteoarthritis, osteo-
porosis and anaemia are all combined. This suggests that
miR-204&211-RUNX2 axis in human MSCs might play a
significant role in the pathogenesis of this rapidly
increasing disease in technologically advanced areas,
and indicate a possible pharmacologic approach to
regenerate homeostasis.
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